Helical tomotherapy of lymph node-negative early-stage breast cancer after breast-conserving surgery

• Verfasst von: Zwicker, Felix [VerfasserIn]
• Verfasst von: Klepper, Rudolf [VerfasserIn]
• Verfasst von: Hauswald, Henrik [VerfasserIn]
• Verfasst von: Hoefel, Sebastian [VerfasserIn]
• Verfasst von: Raether, Luis [VerfasserIn]
• Verfasst von: Huber, Peter E. [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Schempp, Michael [VerfasserIn]
• Titel: Helical tomotherapy of lymph node-negative early-stage breast cancer after breast-conserving surgery
• Titelzusatz: long-term results
• Verf.angabe: Felix Zwicker, Rudolf Klepper, Henrik Hauswald, Sebastian Hoefel, Luis Raether, Peter E. Huber, Juergen Debus, Michael Schempp
• E-Jahr: 2023
• Jahr: April 25, 2023
• Umfang: 13 S.
• Fussnoten: Gesehen am 05.07.2023
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Attiki, 2004
• Jahr Quelle: 2023
• Band/Heft Quelle: 43(2023), 5 vom: Apr., Seite 2041-2053
• ISSN Quelle: 1791-7530
• DOI: doi:10.21873/anticanres.16365
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Breast cancer
• Sach-SW: helical IMRT
• Sach-SW: long-term results
• Sach-SW: lymph node negative
• Sach-SW: lymphedema
• Sach-SW: radiotherapy
• Sach-SW: secondary malignoma
• Sach-SW: tomotherapy
• K10plus-PPN: 1851792163

Abstract

Background/Aim: Adjuvant radiotherapy is an integral part of the interdisciplinary curative treatment of breast cancer. We aimed to examine the long-term clinical results of helical tomotherapy in female patients with local restricted, lymph node negative breast cancer after breast-conserving surgery. Patients and Methods: In this single-centre analysis, 219 female patients with early-stage breast cancer (T1/2) and no lymph node metastasis (N0) following breast-conserving surgery and sentinel-node biopsy were treated with adjuvant fractionated whole breast radiation therapy using helical tomotherapy. When boost irradiation was indicated, it was administered sequentially or using the simultaneous-integrated boost technique. Local control (LC), metastasis and survival rates, acute toxicity, late toxicity, and secondary malignancy rates were analysed retrospectively. Results: The mean follow-up time was 71 months. The 5- and 8-year overall survival (OS) rates were 97.7% and 92.1%, respectively. The 5- and 8-year LC rates were 99.5% and 98.2%, while the 5- and 8-year metastasis-free survival (MFS) rates of 97.4% and 94.3%, respectively. Patients with G3 grading or negative hormone receptor status did not show significantly different results. Acute erythema occurred in 79% (grade 0-2) and 21% (grade 3) of the patients. Lymphedema of the ipsilateral arm and pneumonitis occurred in 6.4% and 1.8% of the treated patients. None of the patients developed >grade 3 toxicities during follow-up, while 1.8% developed a secondary malignancy during follow-up. Conclusion: Helical tomotherapy showed excellent long-term results and low toxicity rates. The incidence rates of secondary malignancy were relatively low and correlated with pre-existing data on radiotherapy, suggesting wider implementation of helical tomotherapy in adjuvant radiotherapy for breast cancer patients.